BRISBANE, Calif. / Jun 03, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced in conjunction with the 2024 American Transplant Congress, the publication in Nature Medicine1 of findings from the largest, real-world study of its kind, assessing the role of AlloSure® donor-derived cell-free DNA (dd-cfDNA) and of an AI-enabled rejection risk prediction model, AlloView™ that incorporates AlloSure to improve detection, characterization, and treatment of kidney allograft rejection.
“This landmark study in Nature Medicine further establishes the clinical utility of AlloSure Kidney and the added value of AlloView, our AI-enabled risk prediction model, in detecting the presence, activity and severity of allograft rejection. These findings contribute to a growing body of evidence establishing new standards globally in the routine monitoring of rejection and treatment response in kidney transplant patients," said John W. Hanna, President & CEO of CareDx.
The international multicenter study of 2,882 patients with AlloSure Kidney dd-cfDNA levels and matched biopsy results was conducted by the Paris Institute for Transplantation and Organ Regeneration along with researchers in the U.S. and Belgium. The study evaluated AlloSure Kidney and used AlloView, an AI-enabled risk prediction model, to predict rejection by combining AlloSure with standard of care measures, including estimated glomerular filtration rate (eGFR), proteinuria, change in serum creatinine, donor-specific antibodies (DSA), and previous history of rejection.
The study results published in Nature Medicine demonstrated the following1:
“This study underscores AlloSure dd-cfDNA’s role as a real-time indicator of kidney transplant rejection, enabling clinicians to intervene earlier before rejection occurs and to monitor post-treatment progress without resorting to unnecessary biopsy procedures,” said Alexandre Loupy, MD, PhD, Professor of Nephrology and Statistics at Necker Hospital, and Director of the Paris Institute of Transplantation and Organ Regeneration at the French National Institute of Health (Inserm).
CareDx’s AlloSure dd-cfDNA was made commercially available in 2017, the industry’s first dd-cfDNA for use to non-invasively identify the risk of allograft injury and rejection in kidney transplantation. Since then, AlloSure has also become available for clinical use in heart and lung transplant recipients. AlloView, an AI-enabled risk prediction model is now commercially available. AlloView optimizes patient risk prediction by integrating artificial intelligence, AlloSure and standard of care measures.2
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey; and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward-Looking Statements
This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with AlloSure and AlloView. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of AlloSure and AlloView; risks that the findings in the Nature Medicine study supporting the data may be inaccurate; general economic and market factors; and other risks discussed in CareDx’s filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, the quarterly report on Form 10-Q for the quarter ended March 31, 2024 filed by CareDx with the SEC on May 9, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
References
Last Trade: | US$27.10 |
Daily Change: | -0.03 -0.11 |
Daily Volume: | 646,145 |
Market Cap: | US$1.430B |
May 09, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB